Yifu F. He
Hefei, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications
Safety of fruquintinib mono- and combo therapy in metastatic colorectal cancer: real-world subgroup analysis from China.
Journal: Future oncology (London, England)
Published: May 28, 2026
Efficacy and safety of camrelizumab-based regimens in advanced squamous cell carcinoma patients: a prospective multicenter study.
Journal: Frontiers in pharmacology
Published: December 13, 2025
Chinese consensus on first-line precision therapy for advanced gastric cancer.
Journal: Innovation (Cambridge (Mass.))
Published: September 16, 2025
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.
Journal: Nature medicine
Published: March 27, 2025
Safety of fruquintinib in Chinese patients with colorectal cancer: an age subgroup analysis from a phase IV real-world clinical practice study.
Journal: Therapeutic advances in medical oncology
Published: March 10, 2025
The application of QCT in the prognostic assessment of mCRC undergoing first-line treatment based on bevacizumab.
Journal: Future oncology (London, England)
Published: November 19, 2024
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial.
Journal: The lancet. Gastroenterology & hepatology
Published: November 13, 2024
A machine learning model utilizing CT radiomics features and peripheral blood inflammatory markers predicts the prognosis of patients with unresectable esophageal squamous cell carcinoma undergoing PD-1 inhibitor combined with concurrent chemoradiotherapy.
Journal: Journal of Cancer
Published: October 14, 2024
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.
Journal: Nature medicine
Published: September 29, 2024
Spontaneous evolution of density peaking factor in TEM turbulence-dominated H-mode plasma on the EAST Tokamak.
Journal: Scientific reports
Published: September 13, 2024
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial.
Journal: Journal of hematology & oncology
Published: August 05, 2024
Last Updated: 09/26/2026